Complete Remission with Inotuzumab Ozogamicin as Fourth-Line Salvage Therapy in a Child with Relapsed/Refractory Acute Lymphoblastic Leukemia

Complete Remission with Inotuzumab Ozogamicin as Fourth-Line Salvage Therapy in a Child with Relapsed/Refractory Acute Lymphoblastic Leukemia

<b>Background:</b> Despite the progress achieved regarding survival rates in childhood acute lymphoblastic leukemia (ALL), relapsed or refractory disease still poses a therapeutic challenge. Inotuzumab ozogamicin is a CD22-directed monoclonal antibody conjugated to calicheamicin, which h...

Full description

Saved in:
Bibliographic Details
Main Authors: Athanasios Tragiannidis, Vassiliki Antari, Eleni Tsotridou, Theodoros Sidiropoulos, Aikaterini Kaisari, Maria Palabougiouki, Timoleon-Achilleas Vyzantiadis, Emmanuel Hatzipantelis, Assimina Galli-Tsinopoulou, Evgenios Goussetis
Format: Article
Language:English
Published: MDPI AG 2024-09-01
Series:Hematology Reports
Subjects:
acute lymphoblastic leukemia
inotuzumab ozogamicin
childhood
Online Access:https://www.mdpi.com/2038-8330/16/4/56
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items